Method of preventing adverse effects by GLP-1
First Claim
1. A method for the treatment of hyperglycemia or diabetes in a patient, comprising the step of administering prandially to a patient in need of treatment an inhalable rapid-acting dry powder GLP-1 formulation, the dry powder formulation comprising microparticles comprising a therapeutically effective amount of a GLP-1 molecule in an amount of at least about 0.5% by weight and a diketopiperazine, wherein the weight ratio of diketopiperazine to GLP-1 is at least about 17:
- 3, and a dipeptidyl peptidase-IV (DPP-IV) inhibitor, and wherein the GLP-1 formulation comprises about 0.5 mg to about 3 mg of GLP-1 dose.
7 Assignments
0 Petitions
Accused Products
Abstract
A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.
149 Citations
20 Claims
-
1. A method for the treatment of hyperglycemia or diabetes in a patient, comprising the step of administering prandially to a patient in need of treatment an inhalable rapid-acting dry powder GLP-1 formulation, the dry powder formulation comprising microparticles comprising a therapeutically effective amount of a GLP-1 molecule in an amount of at least about 0.5% by weight and a diketopiperazine, wherein the weight ratio of diketopiperazine to GLP-1 is at least about 17:
- 3, and a dipeptidyl peptidase-IV (DPP-IV) inhibitor, and wherein the GLP-1 formulation comprises about 0.5 mg to about 3 mg of GLP-1 dose.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
9. A method for reducing glucose levels in a Type 2 diabetic patient suffering from hyperglycemia, the method comprising the step of administering to said patient in need of treatment an inhalable rapid-acting dry powder GLP-1 formulation for pulmonary administration, said dry powder inhalable formulation comprising microparticles comprising a therapeutically effective amount of GLP-1 in an amount of at least about 0.5% by weight and a diketopiperazine or pharmaceutically acceptable salt thereof, wherein the weight ratio of diketopiperazine to GLP-1 is at least about 17:
- 3, and a DPP-IV inhibitor, and wherein the GLP-1 formulation comprises about 0.02 mg to about 2 mg of GLP-1 dose.
- View Dependent Claims (10, 11, 12, 13, 14, 15, 16, 17)
-
18. A method for the treatment of hyperglycemia or diabetes in a patient, comprising the step of administering prandially to a patient in need thereof an inhalable rapid-acting dry powder GLP-1 formulation, the dry powder formulation comprising microparticles comprising a therapeutically effective amount of a GLP-1 molecule and a diketopiperazine, and a DPP-IV inhibitor;
- wherein the weight ratio of diketopiperazine to GLP-1 is at least about 17;
3, wherein said GLP-1 reaches a peak plasma concentration greater than 100 pMol/L by 6 minutes after administration, and wherein the GLP-1 formulation comprises about 0.5 mg to about 3 mg of GLP-1 dose. - View Dependent Claims (19, 20)
- wherein the weight ratio of diketopiperazine to GLP-1 is at least about 17;
Specification